RobertLawrenceGottliebMDPhD, FACC, FAST, FIDSA

Adult Congenital Heart Disease, Heart Failure & Transplantation, Cardiothoracic Imaging, Cardiovascular Disease Genetics

Physician

Join to view full profile

Dr. Gottlieb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gottlieb's full profile

Already have an account?

Office
Baylor Center for Advanced Heart and Lung Disease
3410 Worth Street
Dallas, TX 75246
Phone+1 214-820-6856

Fax+1 214-820-1474
Is this information wrong?

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Cardiovascular Disease, 2007 - 2012
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2005 - 2007
University of Colorado School of Medicine Anschutz Medical CampusClass of 2005

Certifications & Licensure

TX State Medical License 2015 - 2025
NC State Medical License 2013 - 2024
IA State Medical License 2005 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
American Board of Internal Medicine Cardiovascular Disease
National Board of Physicians and Surgeons Advanced Heart Failure and Transplant
National Board of Physicians and Surgeons Cardiovascular Disease
National Board of Physicians and Surgeons Internal Medicine

Awards, Honors, & Recognition

Fellow (FACC) American College of Cardiology
Fellow (FIDSA) Infectious Disease Society of America
Fellow (FAST) American Society of Transplantation

Clinical Trials

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients Start of enrollment: 2018 Mar 20
Active, not recruiting
Phase 2
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Start of enrollment: 2018 Jan 18
Completed
Phase 3
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Start of enrollment: 2018 Mar 13
Completed
Phase 3
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation Start of enrollment: 2018 Apr 17
Terminated
Phase 3
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Start of enrollment: 2020 Mar 15
Completed
Phase 3
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) Start of enrollment: 2020 Mar 06
Completed
Phase 3
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) Start of enrollment: 2020 Apr 15
Completed
Phase 2
MSCs in COVID-19 ARDS Start of enrollment: 2020 Apr 30
Terminated
Phase 3
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 Start of enrollment: 2020 Apr 24
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia Start of enrollment: 2020 Jun 16
Completed
Phase 3
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness Start of enrollment: 2020 Jun 17
Completed
Phase 2, Phase 3
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting Start of enrollment: 2020 Sep 18
Terminated
Phase 3
ACTIV-3: Therapeutics for Inpatients With COVID-19 Start of enrollment: 2020 Aug 04
Completed
Phase 3
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation Start of enrollment: 2020 Sep 14
Completed
Phase 1, Phase 2
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Start of enrollment: 2020 Oct 29
Completed
Phase 2
Cardiopulmonary Stress Testing (CPET) AlloSure Study Start of enrollment: 2020 May 21
Recruiting
The ARIES HeartMate 3 Pump IDE Study Start of enrollment: 2020 Jul 14
Completed
Not Applicable
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) Start of enrollment: 2022 Aug 16
Recruiting
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Start of enrollment: 2022 Dec 14
Recruiting
Phase 3
Study of Obeldesivir in Nonhospitalized Participants With COVID-19 Start of enrollment: 2023 Feb 08
Completed
Phase 3
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness Start of enrollment: 2022 Nov 05
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

21 citations
Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States.
Anand P Chokkalingam, Jennifer Hayden, Jason D Goldman, Hu Li, Julius Asubonteng, Essy Mozaffari, Christopher Bush, Jocelyn R Wang, Amanda Kong, Anu O Osinusi, Robert ...> ;JAMA Network Open. 2022 Dec 1
14 citations
A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19.
Michael E Bowdish, Christina E Barkauskas, Jessica R Overbey, Robert L Gottlieb, Keren Osman, Abhijit Duggal, Mary E Marks, Jonathan Hupf, Eustace Fernandes, Bradley G...> ;American Journal of Respiratory and Critical Care Medicine. 2023 Feb 1
2 citations
Intentions to receive COVID-19 vaccines in the united states: Sociodemographic factors and personal experiences with COVID-19.
Ann Marie Warren, Monica M Bennett, Briget da Graca, Anthony C Waddimba, Robert L Gottlieb, Megan E Douglas, Mark B Powers> ;Health Psychology. 2023 Aug 1
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19.
ACTIV-3/TICO Study Group, Rogers AJ, Wentworth D, Phillips A, Shaw-Saliba K, Dewar RL, Aggarwal NR, Babiker AG, Chang W, Dharan NJ, Davey VJ, Higgs ES, Gerry N, Ginde ...> ;Annals of internal medicine. 2022-08-30
3 citations
Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19.
Cindy Ke Zhou, Monica M Bennett, Carlos H Villa, Kendall P Hammonds, Yun Lu, Jason Ettlinger, Elisa L Priest, Robert L Gottlieb, Steven Davis, Edward Mays, Tainya C Cl...> ;Plos One. 2022 Jan 1
30 citations
Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Soci...
Joelle Nelson, Nicole Alvey, Lyndsey Bowman, Jamie Schulte, Maria Cristina Segovia, Jennifer McDermott, Helen S Te, Nikhil Kapila, Deborah Jo Levine, Robert L Gottlieb...> ;Pharmacotherapy. 2022 Aug 1
17 citations
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.
Gerard J Criner, Frederick M Lang, Robert L Gottlieb, Kusum S Mathews, Tisha S Wang, Todd W Rice, Deepu Madduri, Shashi Bellam, Robert Jeanfreau, Amy H Case, Marilyn K...> ;American Journal of Respiratory and Critical Care Medicine. 2022 Jun 1
10 citations
Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Soci...
Joelle Nelson, Nicole Alvey, Lyndsey Bowman, Jamie Schulte, Maria Cristina Segovia, Jennifer McDermott, Helen S Te, Nikhil Kapila, Deborah Jo Levine, Robert L Gottlieb...> ;Pharmacotherapy. 2022 Aug 1
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.
ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group> ;The Lancet. Respiratory medicine. 2022-07-08
1 citations
Stewardship of COVID-19 volunteers by nested trial design.
Robert L Gottlieb, Raymund R Razonable> ;The Lancet. Infectious Diseases. 2022 Oct 1
Outpatient Remdesivir to Prevent Progression to Severe Covid-19. Reply.
Gottlieb RL, Juneja K, Hill JA> ;The New England journal of medicine. 2022-02-16
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, ...> ;The New England journal of medicine. 2022-02-09
1 citations
New molecular microscope archetypes: Will the real rejection please stand up?
Robert L Gottlieb, Amit Alam, Medhat Askar> ;The Journal of Heart and Lung Transplantation. 2022 May 1
3 citations
Psychological differences in adults with and without a COVID-19 diagnosis.
Briget da Graca, Monica M Bennett, Robert L Gottlieb, Anthony C Waddimba, Ann Marie Warren, Powers, M.> ;Journal of Mental Health. 2022 Aug 1
Not all shock is created equal.
Amit Alam, Timothy Gong, Robert L Gottlieb> ;The American Journal of Emergency Medicine. 2022 Jul 1
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomise...
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group> ;The Lancet. Infectious diseases. 2021-12-23
653 citations
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Robert L Gottlieb, Carlos E Vaca, Roger Paredes, Jorge Mera, Brandon J Webb, Gilberto Perez, Godson Oguchi, Pablo Ryan, Bibi U Nielsen, Michael Brown, Ausberto Hidalgo...> ;The New England Journal of Medicine. 2022 Jan 27
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
ACTIV-3/TICO Bamlanivimab Study Group*> ;Annals of internal medicine. 2021-12-21
16 citations
ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case r...
Katalin Martits-Chalangari, Cedric W Spak, Medhat Askar, Aaron Killian, Tammy L Fisher, Ercem Atillasoy, William L Marshall, David McNeel, Michael D Miller, Susan K Ma...> ;American Journal of Transplantation. 2022 Apr 1
16 citations
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Lin Zhang, Josh Poorbaugh, Michael Dougan, Peter Chen, Robert L Gottlieb, Gregory Huhn, Stephanie Beasley, Montanea Daniels, Thi Ngoc Vy Trinh, Melissa Crisp, Joshua J...> ;Frontiers in Immunology. 2021 Jan 1
Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, G...> ;The New England journal of medicine.
4 citations
Early psychological health outcomes among United States healthcare professionals, essential workers, and the general population during the COVID-19 pandemic: The influ...
Ann Marie Warren, Monica Bennett, Valerie Danesh, Anthony C. Waddimba, Mario Tovar, Robert L. Gottlieb, Mark B. Powers> ;Psychiatry Research Communications. 2021 Dec 1
19 citations
A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic...
Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L. Gottlieb, Peter Chen, Corey Hebert, Russell Perry, Joseph Boscia, Barry Heller, Jason Morris, Chad Crystal, A...> ;Clinical Infectious Diseases. 2021 Oct 28
78 citations
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Ivan O. Rosas, George A. Diaz, Robert L. Gottlieb, Suzana Margareth Lobo, Philip Robinson, Bradley D. Hunter, Adilson W. Cavalcante, J. Scott Overcash, Nicola A. Hanan...> ;Intensive Care Medicine. 2021 Oct 5
60 citations
Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort.
Essy Mozaffari, Aastha Chandak, Zhiji Zhang, Shuting Liang, Mark Thrun, Robert L. Gottlieb, Daniel R. Kuritzkes, Paul E. Sax, David A. Wohl, Roman Casciano, Paul Hodgk...> ;Clinical Infectious Diseases. 2021 Oct 1
Join now to see all

Journal Articles

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Robert L Gottlieb, Joseph Boscia, Gregory Huhn, Valentina Stosor, Imad Shawa, The New England Journal of Medicine
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Robert L Gottlieb, Joseph Boscia, Gregory Huhn, Valentina Stosor, Imad Shawa, The New England Journal of Medicine
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19
Robert L Gottlieb, Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Gregory Huhn, JAMA

Authored Content

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Join now to see all

Press Mentions

Remdesivir use associated with increased survival among patients with COVID-19October 27th, 2023
Doctors Have an Arsenal of Covid-19 Treatments, but Setbacks and Shortages Are Undercutting OptionsJanuary 7th, 2022
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19December 23rd, 2021
Join now to see all